DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG

H3 K27M-mutant gliomas often manifest as midline gliomas, have a dismal prognosis, and have no effective treatments. ONC201 efficacy has been shown in high-grade glioma preclinical models and durable responses with single agent ONC201 have been reported in adults with recurrent H3 K27M-mutant glioma...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Gardner, Sharon, Tarapore, Rohinton, Allen, Jeffrey, Zaky, Wafik, Odia, Yazmin, Hall, Matthew, Daghistani, Doured, Khatib, Ziad, Koschmann, Carl, Aguilera, Dolly, MacDonald, Tobey, Fouladi, Maryam, McGovern, Susan, Kline, Cassie, Vitanza, Nicholas, Lu, Guangrong, Merdinger, Krystal, Oster, Wolfgang, Allen, Joshua, Khatua, Soumen
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Diffuse Midline Glioma/DIPG
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715960/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.097
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items